An observational study in Cavernous Malformation, Cerebral, Cavernous Angioma and Cavernous Hemangioma, sponsored by yuanli Zhao. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-04.
Sponsored by yuanli Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Seizures with a site in China — 14 open to participants now, 16 under way, 9 of them phase 3. Seizures · China.
Among the 39 studies in Seizures with a site in China, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2019, is one of 13 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 18th registered.
766 studies on the registry are indexed under Seizures; 133 are open to participants now.
Browse Seizures studies →14 of the 39 studies in Seizures with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Epygenix · Sites in China, United States, Hungary and 7 more countries
Ages 2–55
UCB Biopharma SRL · Sites in China, United States, Australia and 10 more countries
Ages 12+
Wei Zhao · Sites in China
Ages 65–100
Epygenix · Sites in China, United States, Argentina and 8 more countries
Ages 2+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19
First in 2006; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 140 across 216 observational studies indexed under Seizures.
Median enrollment 280 across the 26 interventional studies, 500 across the 13 observational. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 39 have an industry lead sponsor. The 10 most frequent:
yuanli Zhao is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
yuanli Zhao has 1 study filed under Seizures — fewer than ten, so there is no comparison to draw.
7 of the studies in Seizures with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT05077904Phase 3UCB Biopharma SRLA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | 2027-03-29 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Seizures with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.
The CRESS study is a prospective observational study of imaging biomarker for cerebral cavernous malformation (CCM) related epilepsy (CRE) risk in natural history or after surgical resection. This project, funded by the National Nature Science Foundation of China, will be performed in two sites: Bejing Tiantan Hospital, Capital Medical University and Peking University International Hospital, which cover the south and north part of Beijing. Bejing Tiantan Hospital is also the China National Clinical Research Center for Neurological Diseases and the largest neurological center with high volume of patients all over the nation.
Study overview: Each participants will be followed for 5 year since enrollment. Epilepsy will be tracked with serial video EEG recordings and clinical investigations performed annually. Besides medical history of the patients, data from seizure diary and MR imaging studies (including quantitative susceptibility mapping, diffusion tensor imaging and three dimension-T1 weighted imaging), will be collected. Blood samples and tissue samples of surgical resected lesion for biomarkers studies will also be collected in all participants of the project. The data obtained in participants of CCM with or without epilepsy will be compared.
Sample size: Investigators plan to enroll 200 CCM patients in 24 months and follow up for 5 years. Based upon the preliminary results and extensive literature review, investigators predict that about 50% of participants will undergo surgical treatment, while 25% of participants remain suffering from seizure after treatment.
Study endpoints: The primary clinical endpoint of this study is a collection of a set of clinical, molecular, and MRI data in all participants.
Outpatient and inpatient referred to Beijing Tiantan Hospital and Peking University International Hospital who diagnosed with cerebral cavernous malformation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
Perilesional mean QSM in CCM with conservative treatment
Each patient contributes five outcome measurements (at annual image of 5-year follow-up). Perilesional QSM measurements will be performed at baseline and at annual epoch of image. Perilesional mean QSM (in parts per million, ppm) in each study group will be evaluated using univariate comparison and a repeated measures analysis implemented as an unadjusted linear mixed model.
Time frame: End of study (5-year) MRI scan
Perilesional mean QSM after surgical resection of CCM lesion
Each patient contributes three outcome measurements (at year 1 and 2 and 3 after surgery). Perilesional QSM measurements will be performed at annual imaging follow-up after surgery. Mean QSM (in parts per million, ppm) in patients with or without postoperative seizure will be evaluated using univariate comparison and a repeated measures analysis implemented as an unadjusted linear mixed model.
Time frame: End of study (3-year) MRI scan after surgery
Ratio of seizure freedom during follow-up
Seizure freedom, defined as Engel Classification of Post-treatment Outcome Class I, will be assessed annually during follow-up period. For patients with medical treatment or conservative observation, the follow-up period begins since enrollment. For patients with surgical resection, the follow-up period begins after surgery.
Time frame: End of follow-up period (5-year)
Grey matter volume in CCM with epilepsy
The presurgical grey matter volume will be calculated from three dimension T1 weighted imaging. Data of CCM with or without epilepsy will be compared and to detect the correlation between grey matter volume and seizure severity (Liverpool Seizure Severity Scale) and frequency.
Time frame: End of study (5-year) MRI scan
Whole-brain connectome in CCM with epilepsy
Whole-brain connectome will be reconstructed from whole-brain diffusion tensor imaging before surgical treatment. Data of CCM with or without epilepsy will be compared.
Time frame: End of study (5-year) MRI scan
Plan to share: Yes — Study Protocol to be published in peer-reviewed journal
Supporting information: Study protocol
Time frame: Since the publication of study protocol
Access criteria: Available from the principle investigator upon reasonable request
Started Sep 2019 (actual). Primary completion is estimated for Dec 2026, 87 months after the start.
Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 87 months is above that.
Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.